BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24461648)

  • 1. Association between genetic polymorphisms in apoptosis-related genes and risk of cutaneous melanoma in women and men.
    Oliveira C; Lourenço GJ; Rinck-Junior JA; Cintra ML; Moraes AM; Lima CS
    J Dermatol Sci; 2014 May; 74(2):135-41. PubMed ID: 24461648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms in apoptosis-related genes in cutaneous melanoma prognosis: sex disparity.
    Oliveira C; Lourenço GJ; Rinck-Junior JA; de Moraes AM; Lima CS
    Med Oncol; 2017 Feb; 34(2):19. PubMed ID: 28050764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of BCL2-938C>A and BAX-248G>A promoter polymorphisms in the development of AML: case-control study from South India.
    Cingeetham A; Vuree S; Dunna NR; Gorre M; Nanchari SR; Edathara PM; Meka P; Annamaneni S; Digumarthi R; Sinha S; Satti V
    Tumour Biol; 2015 Sep; 36(10):7967-76. PubMed ID: 25957891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the XPC (A2920C), XPF (T30028C), TP53 (Arg72Pro) and GSTP1 (Ile105Val) polymorphisms in the risk of cutaneous melanoma.
    Oliveira C; Rinck-Junior JA; Lourenço GJ; Moraes AM; Lima CS
    J Cancer Res Clin Oncol; 2013 Jul; 139(7):1199-206. PubMed ID: 23568549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Association of murine double minute 2 and P53 polymorphisms with breast cancer susceptibility].
    Wang ML; Xu YX; Qian J; Wang FH
    Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Feb; 47(2):124-8. PubMed ID: 23719102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck.
    Chen K; Hu Z; Wang LE; Sturgis EM; El-Naggar AK; Zhang W; Wei Q
    Carcinogenesis; 2007 Sep; 28(9):2008-12. PubMed ID: 17693666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 SNP309 promoter polymorphism confers risk for hereditary melanoma.
    Thunell LK; Bivik C; Wäster P; Fredrikson M; Stjernström A; Synnerstad I; Rosdahl I; Enerbäck C
    Melanoma Res; 2014 Jun; 24(3):190-7. PubMed ID: 24625390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of the effect of MDM2 SNP309 and TP53 Arg72Pro polymorphisms on the age of onset of cutaneous melanoma.
    Cotignola J; Chou JF; Roy P; Mitra N; Busam K; Halpern AC; Orlow I
    J Invest Dermatol; 2012 May; 132(5):1471-8. PubMed ID: 22336942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma.
    Firoz EF; Warycha M; Zakrzewski J; Pollens D; Wang G; Shapiro R; Berman R; Pavlick A; Manga P; Ostrer H; Celebi JT; Kamino H; Darvishian F; Rolnitzky L; Goldberg JD; Osman I; Polsky D
    Clin Cancer Res; 2009 Apr; 15(7):2573-80. PubMed ID: 19318491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma.
    Hong Y; Miao X; Zhang X; Ding F; Luo A; Guo Y; Tan W; Liu Z; Lin D
    Cancer Res; 2005 Oct; 65(20):9582-7. PubMed ID: 16230424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.
    Han JY; Lee GK; Jang DH; Lee SY; Lee JS
    Cancer; 2008 Aug; 113(4):799-807. PubMed ID: 18618574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.
    Qiu M; Liu Y; Yu X; Qin L; Bei C; Zeng X; Qiu X; Tang B; He S; Yu H
    Tumour Biol; 2016 Mar; 37(3):3863-70. PubMed ID: 26476535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic association of the polymorphisms in apoptosis-related genes with osteoarthritis susceptibility in Chinese Han population.
    Ma G; Jiang D; Huang J
    Int J Clin Exp Pathol; 2018; 11(4):2221-2226. PubMed ID: 31938334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer.
    Zhang X; Miao X; Guo Y; Tan W; Zhou Y; Sun T; Wang Y; Lin D
    Hum Mutat; 2006 Jan; 27(1):110-7. PubMed ID: 16287156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
    Nan H; Qureshi AA; Hunter DJ; Han J
    Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BAX -248 G>A and BCL2 -938 C>A Variant Lowers the Survival in Patients with Nasopharyngeal Carcinoma and Could be Associated with Tissue-Specific Malignancies: A Multi-Method Approach.
    Chatterjee K; De S; Deb Roy S; Sahu SK; Chakraborty A; Ghatak S; Das N; Mal S; Roy Chattopadhyay N; Das P; Reddy RR; Mukherjee S; Das AK; Puii Z; Zomawia E; Singh YI; Tsering S; Riba K; Rajasubramaniam S; Suryawanshi AR; Choudhuri T
    Asian Pac J Cancer Prev; 2021 Apr; 22(4):1171-1181. PubMed ID: 33906310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness.
    Capasso M; Ayala F; Avvisati RA; Russo R; Gambale A; Mozzillo N; Ascierto PA; Iolascon A
    J Hum Genet; 2010 Aug; 55(8):518-24. PubMed ID: 20535124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
    Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. XPC (A2920C), XPF (T30028C), TP53 (Arg72Pro), and GSTP1 (Ile105Val) polymorphisms in prognosis of cutaneous melanoma.
    Gomez GV; de Oliveira C; Rinck-Junior JA; de Moraes AM; Lourenço GJ; Lima CS
    Tumour Biol; 2016 Mar; 37(3):3163-71. PubMed ID: 26427666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential impact of (rs 4645878) BAX promoter -248G>A and (rs 1042522) TP53 72Arg>pro polymorphisms on epithelial ovarian cancer patients.
    Dholariya S; Mir R; Zuberi M; Yadav P; Gandhi G; Khurana N; Saxena A; Ray PC
    Clin Transl Oncol; 2016 Jan; 18(1):73-81. PubMed ID: 26209050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.